Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
Alamartine
E
E
Service de Néphrologie Dialyse Transplantation Rénale, CHRU de Saint-Etienne, France.
Bellakoul
R
R
Berthoux
F
F
D000208:Acute Disease; D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D006084:Graft Rejection / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3